DOP2014000007A - Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada - Google Patents

Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada

Info

Publication number
DOP2014000007A
DOP2014000007A DO2014000007A DO2014000007A DOP2014000007A DO P2014000007 A DOP2014000007 A DO P2014000007A DO 2014000007 A DO2014000007 A DO 2014000007A DO 2014000007 A DO2014000007 A DO 2014000007A DO P2014000007 A DOP2014000007 A DO P2014000007A
Authority
DO
Dominican Republic
Prior art keywords
union
tnf
antigen
fcrn
incredible
Prior art date
Application number
DO2014000007A
Other languages
English (en)
Inventor
Tejash Shah
Jonathan Henry Ellis
Michael J Molloy
Ian M Tomlinson
Ahmed Yasin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44586854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DOP2014000007A publication Critical patent/DOP2014000007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención provee proteínas de unión a antígeno que se unen específicamente a TNF-alfa. Por ejemplo variantes novedosas de anticuerpos anti-TNF, tal como adalimumab las cuales muestran unión incrementada al receptor FcRn o tiempo de vida media incrementado en comparación con adalimumab. También se proveen composiciones que comprenden las proteínas de unión a antígeno y los usos de dichas composiciones en el tratamiento de trastornos y enfermedad.
DO2014000007A 2011-07-19 2014-01-17 Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada DOP2014000007A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1112429.4A GB201112429D0 (en) 2011-07-19 2011-07-19 Antigen-binding proteins with increased FcRn binding

Publications (1)

Publication Number Publication Date
DOP2014000007A true DOP2014000007A (es) 2014-04-30

Family

ID=44586854

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000007A DOP2014000007A (es) 2011-07-19 2014-01-17 Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada

Country Status (21)

Country Link
US (1) US20130243764A1 (es)
EP (2) EP2734548B1 (es)
JP (1) JP2014524748A (es)
KR (1) KR20140054085A (es)
CN (1) CN103748110A (es)
AU (1) AU2012285786B2 (es)
BR (1) BR112014000341A2 (es)
CA (1) CA2841105A1 (es)
CL (1) CL2014000134A1 (es)
CO (1) CO6862106A2 (es)
CR (1) CR20140029A (es)
DO (1) DOP2014000007A (es)
EA (1) EA201391789A1 (es)
ES (1) ES2600854T3 (es)
GB (1) GB201112429D0 (es)
MA (1) MA35345B1 (es)
MX (1) MX2014000739A (es)
PE (1) PE20141660A1 (es)
SG (1) SG10201601154QA (es)
WO (1) WO2013011076A2 (es)
ZA (1) ZA201400062B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN104159614A (zh) 2012-03-07 2014-11-19 卡迪拉保健有限公司 TNF-α抗体的药物制剂
WO2013158275A1 (en) * 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US20150150982A1 (en) * 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
JP6463268B2 (ja) 2012-09-07 2019-01-30 コヒラス・バイオサイエンシズ・インコーポレイテッド 安定水性アダリムマブ製剤
FR2999431B1 (fr) * 2012-12-17 2016-03-18 Lfb Biotechnologies Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
US20160185847A1 (en) * 2012-12-17 2016-06-30 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
US20150368333A1 (en) * 2013-01-24 2015-12-24 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2836515A1 (en) * 2013-03-14 2015-02-18 AbbVie Inc. Low acidic species compositions and methods for producing and using the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
BR112016000563A2 (pt) * 2013-07-19 2017-09-05 Hexal Ag Método de preparar uma formulação farmacêutica, método de usar ácido hexanóico e/ou ácido cítrico ou pelo menos um sal dos mesmos, formulação farmacêutica e método de modular ou determinar respostas imunes relacionadas à administração de uma formulação farmacêutica
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
AU2014337263B2 (en) * 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
SI2946765T1 (sl) * 2014-05-23 2016-11-30 Ares Trading S.A. Tekoči farmacevtski sestavek
MY192824A (en) * 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
WO2016120413A1 (en) * 2015-01-28 2016-08-04 Mabxience S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016189491A1 (en) * 2015-05-28 2016-12-01 Glaxosmithkline Intellectual Property Development Limited Novel formulation
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2017110980A1 (ja) * 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
UA125378C2 (uk) 2016-03-14 2022-03-02 Універшітетет І Осло МОДИФІКОВАНІ ІМУНОГЛОБУЛІНИ ЗІ ЗМІНЕНИМ ЗВ'ЯЗУВАННЯМ FcRn
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
US11858980B2 (en) 2016-08-02 2024-01-02 Visterra, Inc. Engineered polypeptides and uses thereof
TW202300515A (zh) * 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
CA3049857A1 (en) 2017-01-11 2018-07-19 Celltrion Inc. Stable liquid formulation
EP3569615A4 (en) * 2017-01-13 2020-07-29 Hanx Biopharmaceutics, Inc PROCESS FOR IMPROVING THE BINDING AFFINITY OF AN IGG ANTIBODY TOWARDS FCRN AND PROLONGING THE SERIC HALF-LIFE OF THE latter
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3665195A4 (en) * 2017-08-11 2021-05-19 Research Development Foundation MANIPULATED ANTIBODY FC VARIANTS FOR INCREASED SERUM HALF-VALUE
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
KR20200115568A (ko) * 2018-01-26 2020-10-07 젠자임 코포레이션 FcRn에 대한 증진된 결합 및 연장된 반감기를 갖는 Fc 변이체
TW202330032A (zh) * 2021-11-30 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種抗ｓｏｓｔ抗體醫藥組成物及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230515B1 (hu) * 1996-02-09 2016-10-28 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazásai
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1355919B1 (en) * 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ES2523666T3 (es) 2005-05-31 2014-11-28 Board Of Regents, The University Of Texas System Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
NZ613356A (en) * 2006-10-27 2015-02-27 Abbvie Biotechnology Ltd Crystalline anti-htnfalpha antibodies
KR101637533B1 (ko) 2007-08-20 2016-07-11 글락소 그룹 리미티드 제조 방법
GB2468232B (en) * 2007-11-30 2012-10-24 Glaxo Group Ltd Antigen-bindng constructs
NZ585702A (en) * 2007-11-30 2013-08-30 Abbott Lab Protein formulations and methods of making same
WO2009073805A2 (en) * 2007-12-04 2009-06-11 Verdezyne, Inc. Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
CA2703997C (en) * 2007-12-26 2017-04-04 Xencor, Inc. Fc variants with altered binding to fcrn
US8399627B2 (en) * 2007-12-31 2013-03-19 Bayer Pharma AG Antibodies to TNFα
FR2934599B1 (fr) 2008-07-29 2012-12-21 Arkema France Fabrication de polyethylene a partir de matieres renouvelables, polyethylene obtenu et utilisations
BR122018013284B1 (pt) * 2008-10-29 2022-03-03 Ablynx N.V Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab
CA2753287A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
NZ611324A (en) * 2009-03-05 2015-02-27 Abbvie Inc Il-17 binding proteins
SG175188A1 (en) 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP2435075A2 (en) * 2009-05-28 2012-04-04 Glaxo Group Limited Antigen-binding proteins
WO2011074965A1 (en) * 2009-12-17 2011-06-23 Stichting Sanquin Bloedvoorziening Methods and means for counteracting an activity of an fc domain
EP2637690B1 (en) 2010-11-11 2016-09-21 AbbVie Biotechnology Ltd HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS

Also Published As

Publication number Publication date
BR112014000341A2 (pt) 2017-02-14
ES2600854T3 (es) 2017-02-13
CA2841105A1 (en) 2013-01-24
SG10201601154QA (en) 2016-03-30
EP2734548A2 (en) 2014-05-28
MA35345B1 (fr) 2014-08-01
WO2013011076A3 (en) 2013-04-04
US20130243764A1 (en) 2013-09-19
AU2012285786B2 (en) 2016-05-12
CL2014000134A1 (es) 2014-07-25
EP3009450A1 (en) 2016-04-20
NZ618897A (en) 2016-02-26
PE20141660A1 (es) 2014-11-21
ZA201400062B (en) 2017-08-30
KR20140054085A (ko) 2014-05-08
CO6862106A2 (es) 2014-02-10
JP2014524748A (ja) 2014-09-25
AU2012285786A1 (en) 2014-02-06
CR20140029A (es) 2014-03-05
EA201391789A1 (ru) 2014-06-30
GB201112429D0 (en) 2011-08-31
MX2014000739A (es) 2014-02-19
CN103748110A (zh) 2014-04-23
EP2734548B1 (en) 2016-08-17
WO2013011076A2 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
DOP2014000007A (es) Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada
CY1122278T1 (el) Αντι il-36r αντισωματα
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
EA201791485A1 (ru) Анти-cd47-антитела и их применения
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
PH12016500823A1 (en) Production of t cell retargeting hetero-dimeric immunoglobulins
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201791768A1 (ru) Иммуномодулирующие агенты
EA201492149A8 (ru) St2-антигенсвязывающие белки
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
EA201492101A1 (ru) Антитела против fcrn
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
MX347020B (es) Anticuerpo contra el csf-1r.
EA201790757A1 (ru) Связывающие антиген cd27l белки
CO6640296A2 (es) Proteínas de unión modificadas que inhiben la interacción de recptor vegf-a
EA201490195A1 (ru) Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
MX343659B (es) Proteínas de unión receptoras fc.
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
EA201492163A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
CO6571881A2 (es) Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer